The POWER BARIATRIC Trial: Physical Outcomes With Exercise Regimens on BARIATRIC Patients (POWER)

October 25, 2023 updated by: Gepner Yftach, Tel Aviv University

This study aims to determine how different types of exercise regimens (resistance, aerobic, or combined exercise regimens) can be used to minimize muscle loss and mobilize body fat in severely obese patients after bariatric surgery (BS), despite the rapid surgery-induced weight loss. Additionally, the study will examine how changes in the intestinal microbiota following BS act as a mediation factor that alter tissue-specific responses in muscle and adipose tissue. The study will also evaluate the effect of different types of exercise regimens on cardiometabolic markers, endocrine response, and physical function following BS.

Sixty sedentary (regular exercise <1 hour per week) candidates to bariatric surgery at Herzliya Medical Center will be recruited to participate in this six-month-long randomized control study. Participants will be randomly assigned to either one of three exercise regimens intervention groups (aerobic, resistance, or a combined exercise regimen combining aerobic and resistance exercises) or a control group that will receive standard care. Training will be supervised and matched for metabolic equivalent (METs). The intervention will take place at the Sylvan Adams Sports Institute at Tel Aviv University and an online platform.

All measurements will be taken at a presurgical baseline assessment and throughout the study, and will include changes of muscle mass and adipose tissue distribution, measured by a 3-Tesla magnetic resonance imaging (MRI); body composition- will be assessed using multichannel bioelectrical impedance (Seca); Bone mass, will be measured by a Dual-energy X-ray absorptiometry (DEXA); microbiota composition and changes will be evaluated by stool samples that will be subjected to 16S ribosomal ribonucleic acid (16s rRNA) profiling and metagenomics analysis; fasting blood samples will be used to examine endocrine control and cardiometabolic markers; anthropometric measurements to assess surgery results associations with physical activity outcomes and physical function will be assessed by several validated performance assessments, including handgrip, six-minute walk, sit-to-stand, maximum voluntary contraction, and maximal oxygen consumption (VO2max).

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The primary aim will be to determine how different types of exercise regimens (resistance, aerobic, or combined exercise regimens) can be used to minimize muscle loss and mobilize body fat in severely obese patients after BS, despite the rapid surgery-induced weight loss.

Secondary aims will include: I. To examine the effect of different exercise regimens on the composition and diversity of microbiomes, and their role in mediating muscle mass preservation following BS. II.Evaluate changes in cardiometabolic markers and endocrine response to different exercise regimens and evaluates microbiome mediation of these changes after BS. III.Assess the effect of different exercise regimens on physical function among patients following BS. IV.Clarify the mechanisms of muscle preservation and fat loss involving hormonal response and atrophy related-genes expression.

After baseline measurements (detailed below), participants will be randomized into one of four groups: 1. control group (n=15) that includes routine health care; 2. aerobic exercise training group (n=15), 3. resistance exercise training group (n=15), 4. combined aerobic and resistance exercise training group (n=15). Training sessions will be both in-person and as online exercise supervision. All groups will be supported by a dietitian as part of the routine health care after the bariatric surgery. The dietetic program for all groups will consist of a balanced diet by diet progression guidelines for bariatric patients (XX,ZZ) and the bariatric food pyramid (55). The protein content will be a minimum of 60 gr/protein per day, according to current guidelines (XX,ZZ) . Each training session will increase gradually up to 60 minutes per session, three times a week. Participants will be randomized into 4 groups for 26 weeks of intervention including aerobic, resistance, combined exercise training (aerobic + resistance) and a control group without exercise training.

All exercise training will be matched in metabolic equivalent (METs) and the time of training per week. Participants will begin a two weeks exercise adaptation period at 3-4 postoperative weeks. The activity adaptation plan will consist of 15-20 min. of walking, three times per week, at an intensity of 40-60% of peak oxygen consumption (VO2) or rate of perceived exertion (RPE) 4-6 on the Borg scale for all intervention groups. Following this period, each group will participate in a specific progressive training with the following regimen:

  1. Aerobic exercise training group, weeks 5-8 after surgery: this training will consist of 30 min. of walking, 3 times per week at an intensity of 60-70% of peak VO2 or RPE 6-7 on Borg scale.

    Weeks 9-26 after surgery: this training will consist of 60 minutes of exercise, 3 times per week at an intensity of 65-80% of peak VO2 or RPE 6-8 on the Borg scale. The aerobic exercises will consist of a treadmill or outside walking or running, stationary cycling or elliptical trainer in continuous and interval training.

  2. Resistance exercise training group, weeks 5-8 after surgery: this training will consist of 5-10 minutes of warmup, followed by 6-8 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. The intensity will increase on weeks 9-26 after surgery to 8-10 multi-joint exercises of 3-4 sets of 10 to 25 repetitions. For this training participants will use free-weights and bodyweight exercises.
  3. The combination exercise training will consist of a combined aerobic and resistance exercise training sessions three times weekly. At weeks 5-8 after surgery, the sessions will include 5-10 minutes of warmup, followed by 3-4 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. Afterward, the aerobic part of the training will consist of 10-15 minutes of aerobic exercises (treadmill or outside walking or running, stationary cycling or outdoors or elliptical trainer) at 60-70% of peak VO2 or RPE 6-7 at Borg scale.

    The intensity will increase on weeks 9-26 after surgery to 4-5 multi-joint exercises of 3-4 sets of 10 to 25 repetitions and 30 minutes of aerobic exercises at 65-80% of peak VO2 or RPE 6-8 at Borg scale.

  4. The control group will receive conventional treatment so as the other groups (medical and nutritional follow up).

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Other
      • Tel Aviv, Other, Israel, 6997801
        • Recruiting
        • Tel Aviv University
        • Contact:
          • Yftach Gepner

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Sedentary participants: regular exercise performed <1 hour per week
  • Candidates for primary bariatric surgery at Herzliya Medical Center in accordance to the National Institutes of Health (NIH) criteria for surgery: (body mass index (BMI) > 40 without coexisting co-morbidities or BMI > 35 with > 1 severe obesity-related comorbidities)
  • Sex: all
  • Age: 18 to 65 years.

Exclusion Criteria:

  • Severe cardiopulmonary disease (e.g., recent myocardial infarction or unstable angina)
  • Musculoskeletal or neuromuscular impairments that preclude exercise training
  • Cognitive impairments
  • Use of drugs that affect bone or muscle metabolism (mainly steroids)
  • Patients with previous bariatric surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aerobic exercise training

The aerobic exercise training group, weeks 5-8 after surgery: this training will consist of 30 min. of walking, 3 times per week at an intensity of 60-70% of peak VO2 or RPE 6-7 on the Borg scale.

Weeks 9-26 after surgery: this training will consist of 60 minutes of exercise, 3 times per week at an intensity of 65-80% of peak VO2 or RPE 6-8 on the Borg scale. The aerobic exercises will consist of a treadmill or outside walking or running, stationary cycling or elliptical trainer in continuous and interval training.

Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
Experimental: Resistance exercise training
Resistance exercise training group, weeks 5-8 after surgery: this training will consist of 5-10 minutes of warmup, followed by 6-8 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. The intensity will increase on weeks 9-26 after surgery to 8-10 multi-joint exercises of 3-4 sets of 10 to 25 repetitions. For this training participants will use free-weights and body weight exercises.
Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
Experimental: Combination exercise training

The combination exercise training will consist of a combined aerobic and resistance exercise training sessions three times weekly. At weeks 5-8 after surgery the sessions will include 5-10 minutes of warmup, followed by 3-4 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. Afterwards the aerobic part of the training will consist of 10-15 minutes of aerobic exercises (treadmill or outside walking or running, stationary cycling or outdoors or elliptical trainer) at 60-70% of peak VO2 or RPE 6-7 at Borg scale.

The intensity will increase on weeks 9-26 after surgery to 4-5 multi-joint exercises of 3-4 sets of 10 to 25 repetitions and 30 minutes of aerobic exercises at 65-80% of peak VO2 or RPE 6-8 at Borg scale.

Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
No Intervention: The control group
The control group will receive routine health care without exercise supervision (clinical and nutritional follow up).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle mass (cm3)
Time Frame: At baseline and after 26 weeks of intervention
Changes in thigh muscles volume
At baseline and after 26 weeks of intervention
Body composition - fat mass
Time Frame: At baseline and after 13 and 26 weeks of intervention
Fat mass (Kg)
At baseline and after 13 and 26 weeks of intervention
Body composition
Time Frame: At baseline and after 13 and 26 weeks of intervention
Fat free mass (Kg)
At baseline and after 13 and 26 weeks of intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microbial composition and changes
Time Frame: At baseline and after 13 and 26 weeks of intervention
16S rRNA profiling
At baseline and after 13 and 26 weeks of intervention
Blood measurements - cardiometabolic markers
Time Frame: At baseline and after 13 and 26 weeks of intervention
Cardiometabolic markers: Glucose (mg/dl), lipid profile (total cholesterol in mg/dl, HDL in mg/dl, LDL in mg/dl)
At baseline and after 13 and 26 weeks of intervention
Blood measurements - Insulin
Time Frame: At baseline and after 13 and 26 weeks of intervention
Insulin (pmol/L)
At baseline and after 13 and 26 weeks of intervention
Blood measurements for skeletal muscle metabolism assessment
Time Frame: At baseline and after 13 and 26 weeks of intervention

Levels of anabolic hormones such as growth hormone (ng/ml) (GH), insulin like growth factor (ng/ml) (IGF-1).

Marker of inhibition of skeletal muscle growth: Myostatin (ng/ml)

At baseline and after 13 and 26 weeks of intervention
Blood measurements - Inflammatory markers
Time Frame: At baseline and after 13 and 26 weeks of intervention
Interleukin-6 (pg/ml) (IL6)
At baseline and after 13 and 26 weeks of intervention
Blood measurements for nutritional status
Time Frame: At baseline and after 13 and 26 weeks of intervention
Markers for nutritional status: Hemoglobin (g/dl), albumin (g/dl)
At baseline and after 13 and 26 weeks of intervention
Blood measurements for micronutrients
Time Frame: At baseline and after 13 and 26 weeks of intervention
Ferritin (ng/ml), B12 (ng/ml)
At baseline and after 13 and 26 weeks of intervention
Blood measurements for liver function
Time Frame: At baseline and after 13 and 26 weeks of intervention
Liver enzymes: alanine aminotransferase in units per liter (U/L) (AST), gamma-glutamyltransferase (U/L)(GGT), alanine aminotransferase (U/L) (ALT), alkaline phosphatase (U/L) (ALP);
At baseline and after 13 and 26 weeks of intervention
Blood measurements of adipokines - leptin
Time Frame: At baseline and after 13 and 26 weeks of intervention
Leptin (ng/ml)
At baseline and after 13 and 26 weeks of intervention
Blood measurements of adipokines - adiponectin
Time Frame: At baseline and after 13 and 26 weeks of intervention
Adiponectin (μg/ml)
At baseline and after 13 and 26 weeks of intervention
Blood measurements for bone status
Time Frame: At baseline and after 13 and 26 weeks of intervention
Blood bone markers such as Collagen Type-1 C-Telopeptide in μg/L (CTX) and total procollagen type 1 N-terminal propeptide in μg/L (P1NP).
At baseline and after 13 and 26 weeks of intervention
Bone density changes
Time Frame: At baseline and after 13 and 26 weeks of intervention
Assessed by DEXA scan (T score and g/cm^2)
At baseline and after 13 and 26 weeks of intervention
Anthropometric measurements - BMI
Time Frame: At baseline and after 13 and 26 weeks of intervention
Weight (kg) and height (m) will be combined to calculate BMI (kg/m^2)
At baseline and after 13 and 26 weeks of intervention
waist circumference as part of Anthropometric measurements
Time Frame: At baseline and after 13 and 26 weeks of intervention
waist circumference (cm)
At baseline and after 13 and 26 weeks of intervention
Weight loss percentage outcomes
Time Frame: At baseline and after 13 and 26 weeks of intervention

% Excess weight loss (%EWL) will be calculated by [(initial weight (kg))-(post operative weight(kg))] / [(initial weight in kg) - (ideal body weight in kg)].

Total weight loss % (TWL%) will be calculated by [(initial weight (kg))-(post operative weight(kg))] / initial weight (kg).

At baseline and after 13 and 26 weeks of intervention
Resting metabolic rate
Time Frame: At baseline and after 13 and 26 weeks of intervention
measurement of resting daily energy expenditure (Kcal) will be measured by indirect calorimetry (Kcal/day) and energy expenditure per body kilogram per day (Kcal/Kg/day).
At baseline and after 13 and 26 weeks of intervention

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life (QoL)
Time Frame: At baseline and after 13 and 26 weeks of intervention
Will be assessed by the Bariatric Analysis and Reporting Outcome System (BAROS) questionnaire- measured by the results score
At baseline and after 13 and 26 weeks of intervention
Physical function - 6 min walk test
Time Frame: At baseline and after 13 and 26 weeks of intervention
6 min walk test will be assessed in meters
At baseline and after 13 and 26 weeks of intervention
Physical function - sit to stand test
Time Frame: At baseline and after 13 and 26 weeks of intervention
Sit to stand test will be assessed in seconds
At baseline and after 13 and 26 weeks of intervention
Strength assessment
Time Frame: At baseline and after 13 and 26 weeks of intervention
Will be assessed by performance tests Handgrip test (kg), Estimated one-repetition maximum (the maximum weight a participant can lift, in one attempt, in the bench press and leg press in kg)
At baseline and after 13 and 26 weeks of intervention
Nutritional intake
Time Frame: At baseline and after 13 and 26 weeks of intervention
Will be assessed by validated questionnaires such as food diary. Macronutrients composition will be measured from the self-reported nutritional intake: kcal daily intake, protein intake (in gr and in %of total kcal), carbohydrate intake (in gr and in %of total kcal) and fat intake (in gr and in %of total kcal).
At baseline and after 13 and 26 weeks of intervention
Aerobic fitness - Cardio pulmonary exercise testing
Time Frame: At baseline and after 13 and 26 weeks of intervention
Measurement of submaximal aerobic capacity will be assessed by oxygen consumption (indirect calorimetry) performed on a cycling ergometer, with VO2 reported in ml/kg/min.
At baseline and after 13 and 26 weeks of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Yftach Gepner, Ph.D., Tel Aviv University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2021

Primary Completion (Estimated)

October 30, 2024

Study Completion (Estimated)

October 30, 2024

Study Registration Dates

First Submitted

February 8, 2021

First Submitted That Met QC Criteria

February 25, 2021

First Posted (Actual)

March 2, 2021

Study Record Updates

Last Update Posted (Actual)

October 27, 2023

Last Update Submitted That Met QC Criteria

October 25, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 0010-20-HMC

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Physical activity training

3
Subscribe